Cardiff Oncology's Onvansertib Shows 72.2% Response in Phase 2 RAS-Mutated mCRC Trial

Based on the comprehensive analysis of the available information, I'll draft a news-style article focusing on Cardiff Oncology's clinical trial for onvansertib in RAS-mutated metastatic colorectal cancer.

Title: Cardiff Oncology Advances PLK1 Inhibitor in RAS-Mutated Colorectal Cancer

Cardiff Oncology reported promising results from its Phase 2 CRDF-004 trial of onvansertib, a polo-like kinase 1 (PLK1) inhibitor, in first-line RAS-mutated metastatic colorectal cancer (mCRC). The trial demonstrated a robust objective response rate of 72.2% in patients receiving the 30 mg dose combined with standard chemotherapy, potentially offering a new therapeutic approach for a challenging patient subgroup.

Trial Specifics The randomized Phase 2 trial evaluated onvansertib in combination with FOLFIRI and bevacizumab, comparing different dosing arms against standard of care. The 30 mg onvansertib arm showed particularly promising results, with a progression-free survival (PFS) hazard ratio of 0.37 (p=0.048) and a 94.1% PFS rate at six months. The drug was well-tolerated, with no unexpected safety signals and infrequent grade 3 or higher adverse events.

Next Steps Cardiff Oncology plans to initiate a registrational program in 2026, pending FDA consultation on trial design. The company will likely seek to compare onvansertib with standard FOLFIRI/bevacizumab regimens in a potential pivotal study.

Research Context PLK1 is a critical serine/threonine kinase involved in cell cycle progression, frequently overexpressed in various cancers. Onvansertib selectively inhibits PLK1, potentially disrupting mitotic processes and inducing apoptosis in rapidly dividing tumor cells. This mechanism is particularly relevant in RAS-mutated colorectal cancer, where traditional targeted therapies have limited efficacy.

Competitive Landscape The PLK1 inhibitor space remains challenging, with previous molecules struggling with toxicity. Competing agents like volasertib (Boehringer Ingelheim) and TAK-960 (Takeda) are in earlier stages of development, positioning onvansertib as a potentially differentiated approach.

Disease Background RAS mutations occur in approximately 40-50% of metastatic colorectal cancer cases, significantly limiting treatment options. Current first-line regimens typically involve chemotherapy combinations with bevacizumab, with no approved targeted therapies specifically addressing RAS-mutant tumors.

The trial results suggest onvansertib could offer a meaningful therapeutic option for patients with RAS-mutated mCRC, a population historically underserved by existing treatments. However, further research is needed to confirm these promising early findings.

References:

• CRDF-004 Clinical Trial Details
• Cardiff Oncology Investor Presentation

Would you like me to modify or refine any aspect of the article?

---

Spot something wrong? Report an issue with this article